Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Sponsor
Shi Ming
Study ID
NCT05886257
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Candonilimab — DRUG
    10mg/kg, iv.drip, every 3 week
  • Bevacizumab — DRUG
    15mg/kg, iv.drip, every 3 week

Study Details

To explore the efficacy and safety of candonilimab plus bevacizumab for patients with advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.

Key Dates

First listed
Jun 2, 2023
Start date
Dec 7, 2022
Status verified
Dec 2022
Primary completion
Mar 31, 2023
Completion
Mar 31, 2023

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Candonilimab Plus Bevacizumab
    Candonilimab 10mg/kg, Bevacizumab 15mg/kg, every 3 week

Primary Outcome Measure

ORR per RECIST 1.1 [ Time Frame: 12 months ]

Related Studies